COVID-19 Vaccine Candidates Based on Modified Vaccinia Virus Ankara Expressing the SARS-CoV-2 Spike Protein Induce Robust T- and B-Cell Immune Responses and Full Efficacy in Mice

Authors:

García-Arriaza Juan, Garaigorta Urtzi, Pérez Patricia, Lázaro-Frías Adrián, Zamora Carmen, Gastaminza Pablo, del Fresno Carlos, Casasnovas José M., S. Sorzano Carlos Óscar, Sancho David, Esteban Mariano, Heise Mark T.

Journal:

Journal of Virology

Date of publication:

Wednesday, 10 March, 2021

Volume:

Issue:

Pages:

null

EVAg connections:

Research funded by EVAg

Published by EVAg end-user

EVAg

COVID-19 Vaccine Candidates Based on Modified Vaccinia Virus Ankara Expressing the SARS-CoV-2 Spike Protein Induce Robust T- and B-Cell Immune Responses and Full Efficacy in Mice

EVAg Hotline

For tropical and RG4 viruses

For other human viruses of medical importance

For veterinary pathogens of economic importance

Scientific Publication:

COVID-19 Vaccine Candidates Based on Modified Vaccinia Virus Ankara Expressing the SARS-CoV-2 Spike Protein Induce Robust T- and B-Cell Immune Responses and Full Efficacy in Mice